Faculty: James Bussel, MD, and Emilie Vander Haar, MD; and Andra H. James, MD, MPH, and Kim Roque, MPA (Moderators)
Activity Medical Director: Andra H. James, MD, MPH
In this inaugural Case Conversation session, Dr. Jim Bussel and Dr. Emilie Vander Haar offered case-based insight related to the diagnoses, treatment and management of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The expert faculty featured the upcoming journal article, "New developments in fetal and neonatal alloimmune thrombocytopenia," and reviewed four clinical advances that could radically change the current approach to detection and management of FNAIT, how the treatment of challenging cases could change, and what it means for providers now and in the future. The case presentations and discussion were followed by an interactive Q & A session with participants.
At the conclusion of this program, participants were able to:
- Understand the importance of, and apply to practice, assessing and monitoring patients for the identification of fetal and neonatal thrombocytopenia (FNAIT) in inital and subsequent pregnancies
- Understand the current practice in managing fetal and neonatal alloimmune thrombocytopenia in a subsequent affected pregnancy and its maternal side effects
- Describe four new, effective approaches to testing and treatment to improve fetal, neonatal, and maternal outcomes, as well as the challenges to treatment implementation
- Discuss the ways the intersection of obstetrics and ehmatology and multidisciplinary treatment augmen ts treatment of FNAIT
Target Audience: Ob/Gyn providers, pediatric/adolescent gynecologists, hematologists, nurse practitioners, and other healthcare professionals
The production and archiving of this program were made possible in part by an educational grant from Janssen.